Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech, New Report Launched

The Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech report provides comprehensive understanding and unprecedented access to the preclinical stage partnering deals and agreements entered into by the worlds leading healthcare companies.

Description

The Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech report provides comprehensive understanding and unprecedented access to the preclinical stage partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter preclinical stage partnering deals. The majority of deals are where the licensee obtains a right or an option right to license the licensors product or compound. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest preclinical agreements announced in the healthcare sector.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all preclinical stage partnering deals announced since 2009 including financial terms where available including over 2,000 links to online deal records of actual preclinical partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

This report is formatted to allow direct access to each contract document by deal type agreed by each company listed. Each deal title is linked to an online version of the contract document as filed by the parties with the Securities Exchange Commission.

The initial chapters of this report provide an orientation of preclinical stage deal making and business activities.

Chapter 1 provides an introduction to the report

Chapter 2 provides an overview of why companies partner preclinical stage compounds/products.

Chapter 3 provides an overview of preclinical stage deals strategy and deal structure including numerous case studies.

Chapter 4 provides an overview of the various payment strategies used in preclinical stage deals.

Chapter 5 provides a review of trends in preclinical stage deal making since 2009. Deals are listed by big pharma and big biotech dealmaking in preclinical stage, deal type, therapy type and technology type.

Chapter 6 provides a detailed analysis of preclinical stage payment terms including average headline, upfront, milestone and royalty rates for preclinical deals.

Chapter 7 provides a review of the leading preclinical stage deal by headline value.

Chapter 8 provides a comprehensive listing of the top 50 big pharma and top 50 big biotech companies with a brief summary followed by a comprehensive listing of preclinical stage deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 9 provides a comprehensive and detailed review of preclinical stage partnering deals signed and announced since 2009, where a contract document is available in the public domain. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 10 provides a comprehensive directory of preclinical stage partnering deals since 2009 organized by stage of development – preclinical.

The report also includes numerous tables and figures that illustrate the trends and activities in preclinical stage partnering and deal making since 2009.

In addition, a comprehensive appendix is provided organized by partnering company A-Z , deal type, therapy focus and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of preclinical stage products and compounds.

Benefits

• Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech provides the reader with the following key benefits:
• In-depth understanding of preclinical stage deal trends since 2009
• Access to headline, upfront, milestone and royalty data
• Comprehensive access to over 2,000 preclinical stage deals together with contract documents if available
• Detailed access to actual preclinical stage deals entered into by the leading fifty big pharma and big biotech companies along with other biopharma companies
• Analysis of the structure of preclinical stage agreements with numerous real life case studies
• Identify leading preclinical stage deals by value since 2009
• Identify the most active preclinical stage dealmakers since 2009
• Full listing of preclinical stage deals by company A-Z, phase of development, deal type, therapy and technology focus
• Understand the key deal terms companies have agreed in previous deals
• Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Spanning over 2721 pages, “Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech” report covering the Executive Summary, Introduction, Why do companies partner preclinical stage compounds?, Preclinical stage deal strategies and structure, Trends in preclinical stage deal making, Average payment terms for preclinical stage partnering, Leading preclinical stage deals, Big pharma and big biotech preclinical stage partnering deals, Preclinical stage partnering contracts directory, Preclinical stage dealmaking directory, Appendices. The report covered few companies are - Abbott, Abbott Molecular, Abbvie, Actavis, Actavis (acquired by Watson), Watson Pharmaceuticals, Allergan, Amgen, Astellas, AstraZeneca, Baxter International, Bayer, Bayer Healthcare, Bayer Schering Pharma, Bayer Vital

For more information visit at – http://mrr.cm/Z2D